


Adalimumab (Humira®):

(human monoclonal antibody TNF-alpha inhibiting anti-inflammatory agent)

Adalimumab is used to treat the signs and symptoms of rheumatoid arthritis in adults, juvenile idiopathic arthritis in children, psoriatic arthritis and ankylosing spondylitis in adults plus moderate to severe Crohn's disease.



Adalimumab

An electrochemiluminescence (ECL) assay was developed and validated for adalimumab from 250-10,000 ng/mL. A Mesoscale Streptavidin Gold plate was blocked and then coated with biotinylated TNF-alpha. After addition and incubation of sample on the coated plate, a Sulfo-Tagged Anti-Human Kappa Light Chain Antibody was added and incubated prior to the addition of Read Buffer and analysis on the Mesoscale Sector Imager 6000. The Hamilton Star robotic liquid handling system was used to prepare the Minimum Required Dilutions (MRD) for all samples. [Request a quote](#)

Assay Performance	Adalimumab
Analytical Runs	174
within acceptance criteria	96.9%
Calibration Standards	1390
within acceptance criteria	100%
Quality Controls	1044
within acceptance criteria	99.5%
Mean ISR Reassay Rate	98.1%